Skip to main content
. 2024 Jan 15;16(2):362. doi: 10.3390/cancers16020362

Figure 2.

Figure 2

Axial and sagittal images of a hypofractionated treatment plan delivered to a patient enrolled in the HEROICC clinical trial. Note the simultaneous integrated boost (SIB) to the right external iliac enlarged lymph node with a prescription dose of 46 Gy outlined in red (red arrow) while the remaining pelvis is covered by the 95% prescription isodose line (relative to 40 Gy) outlined in green (green arrow). The prescription dose of 40 Gy runs tightly around CTVs (orange arrow).